Xiuning Le
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
Papers in
-
- Lung Cancer Treatments and Mutations 161
- Lung Cancer Diagnosis and Treatment 14
- Brain Metastases and Treatment 9
- Oncology 31
- Cancer Immunotherapy and Biomarkers 20
- Lung Cancer Research Studies 7
- HER2/EGFR in Cancer Research 5
- Co-authors
- John Victor Heymach (44 shared papers)Monique B. Nilsson (12 shared papers)Tina Cascone (12 shared papers)Sonia A. Patel (4 shared papers)Rakesh K. Jain (1 shared paper)Jianjun J. Zhang (17 shared papers)Lingzhi Hong (11 shared papers)Daniel Botelho Costa (9 shared papers)
- Journals
- Journal of Thoracic Oncology (43 papers)Annals of Oncology (34 papers)Clinical Cancer Research (11 papers)Cancers (8 papers)ESMO Open (7 papers)
- Partner nations
- United StatesChinaJapan
In The Last Decade
Xiuning Le
197 papers receiving 8.1k citations
Xiuning Le's Hit Papers
Peers
Comparison fields: 5 of 116
- Pulmonary and Respiratory Medicine 4.4k
- Oncology 2k
- Cancer Research 509
- Health Informatics 86
- Otorhinolaryngology 94
Countries citing papers authored by Xiuning Le
This map shows the geographic impact of Xiuning Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiuning Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiuning Le more than expected).
Fields of papers citing papers by Xiuning Le
This network shows the impact of papers produced by Xiuning Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiuning Le. The network helps show where Xiuning Le may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiuning Le, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 223 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations Hit paper breakdown → | 2020 | 661 |
| 2 | Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Hit paper breakdown → | 2021 | 494 |
| 3 | Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy Hit paper breakdown → | 2022 | 354 |
| 4 | Structure-based classification predicts drug response in EGFR-mutant NSCLC Hit paper breakdown → | 2021 | 350 |
| 5 | Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC Hit paper breakdown → | 2018 | 338 |
| 6 | Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance Hit paper breakdown → | 2023 | 311 |
| 7 | 2020 | 260 | |
| 8 | Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer Hit paper breakdown → | 2021 | 233 |
| 9 | 2020 | 216 | |
| 10 | 2019 | 190 | |
| 11 | AI in drug discovery and its clinical relevance Hit paper breakdown → | 2023 | 183 |
| 12 | Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial Hit paper breakdown → | 2023 | 173 |
| 13 | 2007 | 161 | |
| 14 | Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial Hit paper breakdown → | 2023 | 154 |
| 15 | 2020 | 153 | |
| 16 | 2020 | 143 | |
| 17 | 2021 | 130 | |
| 18 | CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Hit paper breakdown → | 2024 | 121 |
| 19 | 2016 | 113 | |
| 20 | 2017 | 111 |
About Xiuning Le
Xiuning Le is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Otorhinolaryngology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 223 papers that have together received 8.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (161 papers), Cancer Immunotherapy and Biomarkers (20 papers), Lung Cancer Diagnosis and Treatment (14 papers), Brain Metastases and Treatment (9 papers), Head and Neck Cancer Studies (7 papers), Lung Cancer Research Studies (7 papers), Radiomics and Machine Learning in Medical Imaging (6 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.4k citations), Oncology (2k citations), Cancer Research (509 citations), Health Informatics (86 citations) and Otorhinolaryngology (94 citations). Xiuning Le has collaborated with scholars based in United States, China and Japan. Frequent co-authors include John Victor Heymach, Monique B. Nilsson, Tina Cascone, Sonia A. Patel, Rakesh K. Jain, Jianjun J. Zhang, Lingzhi Hong, Daniel Botelho Costa, Jonathan Wade Goldman and Niamh Coleman. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Clinical Cancer Research, Cancers and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.